SCLC Education
Small cell lung cancer remains aggressive and challenging to treat, but immunotherapy combinations have improved survival in extensive-stage disease. Knowledge Med sessions help community providers navigate evolving treatment algorithms through interactive clinical case simulations.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing small cell lung cancer face evolving treatment decisions that interactive, independently reviewed education can help address.
- Optimizing first-line chemoimmunotherapy in extensive-stage SCLC
- Deciding on prophylactic cranial irradiation vs surveillance
- Managing relapsed disease and selecting second-line therapy
- Incorporating emerging agents including DLL3-targeted therapies
What Sessions Cover
Knowledge Med SCLC sessions use interactive case simulations to address these topics and more.
- First-line immunotherapy-chemotherapy in extensive-stage SCLC
- Limited-stage SCLC: chemoradiation and consolidation strategies
- Second-line options: topotecan, lurbinectedin, and emerging agents
- Supportive care and symptom management in SCLC
Interactive SCLC Sessions
Case Simulations
Work through realistic small cell lung cancer patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key SCLC clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Join a SCLC Session
Third-party, non-promotional small cell lung cancer education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session